European Commission Approves KEYTRUDA^® (Pembrolizumab) As Adjuvant Treatment for Adults with Non-small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Merck announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with NSCLC who are at high risk of recurrence following complete resection and platinum-based chemotherapy.